C Zheng1,2, H Hao1,2, L Chen1,2, J Shao3,4. 1. Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, 330000, China. 2. Jiangxi Province Key Laboratory of Molecular Medicine, Nanchang, 330000, China. 3. Department of General Surgery, Second Affiliated Hospital of Nanchang University, Nanchang, 330000, China. shao5022@163.com. 4. Jiangxi Province Key Laboratory of Molecular Medicine, Nanchang, 330000, China. shao5022@163.com.
Abstract
PURPOSE: Long noncoding RNAs (lncRNAs) are outstanding as novel cancer biomarkers with great prospects. Herein, we focused on summarizing the overall diagnostic evaluation of lncRNAs for hepatocellular carcinoma (HCC). METHODS: Relevant literature was collected from the online databases. The Quality Assessment for Studies of Diagnostic Accuracy checklist was used to assess the quality of included studies. The pooled sensitivity, specificity, and diagnostic odds ratio (DOR) were plotted using random-effects models. Summary receiver operating characteristic curve and the area under the curve (AUC) were used to estimate the overall test performance. Statistical analysis was performed by STATA 14.0 and Meta-DiSc 1.4 software. RESULTS: Ten studies with a total of 820 HCC patients and 785 healthy controls were included. For overall lncRNAs, the pooled sensitivity, specificity, and DOR to predict HCC patients were 80% [95% confidence interval (CI) 77-82%], 79% (95% CI 76-81%), and 27.66 (95% CI 14.26-53.63), respectively, corresponding to an AUC of 0.91. CONCLUSIONS: LncRNAs were a high diagnostic value for HCC and its expression could potentially be used as auxiliary biomarker in confirming HCC.
PURPOSE: Long noncoding RNAs (lncRNAs) are outstanding as novel cancer biomarkers with great prospects. Herein, we focused on summarizing the overall diagnostic evaluation of lncRNAs for hepatocellular carcinoma (HCC). METHODS: Relevant literature was collected from the online databases. The Quality Assessment for Studies of Diagnostic Accuracy checklist was used to assess the quality of included studies. The pooled sensitivity, specificity, and diagnostic odds ratio (DOR) were plotted using random-effects models. Summary receiver operating characteristic curve and the area under the curve (AUC) were used to estimate the overall test performance. Statistical analysis was performed by STATA 14.0 and Meta-DiSc 1.4 software. RESULTS: Ten studies with a total of 820 HCC patients and 785 healthy controls were included. For overall lncRNAs, the pooled sensitivity, specificity, and DOR to predict HCC patients were 80% [95% confidence interval (CI) 77-82%], 79% (95% CI 76-81%), and 27.66 (95% CI 14.26-53.63), respectively, corresponding to an AUC of 0.91. CONCLUSIONS: LncRNAs were a high diagnostic value for HCC and its expression could potentially be used as auxiliary biomarker in confirming HCC.
Authors: Joshua N Honeyman; Elana P Simon; Nicolas Robine; Rachel Chiaroni-Clarke; David G Darcy; Irene Isabel P Lim; Caroline E Gleason; Jennifer M Murphy; Brad R Rosenberg; Lydia Teegan; Constantin N Takacs; Sergio Botero; Rachel Belote; Soren Germer; Anne-Katrin Emde; Vladimir Vacic; Umesh Bhanot; Michael P LaQuaglia; Sanford M Simon Journal: Science Date: 2014-02-28 Impact factor: 47.728
Authors: Paolo Fusar-Poli; Marco Cappucciati; Grazia Rutigliano; Margaret Heslin; Daniel Stahl; Zera Brittenden; Edgardo Caverzasi; Philip McGuire; William T Carpenter Journal: Schizophr Bull Date: 2016-03-15 Impact factor: 9.306
Authors: Ming Li; Ying Wang; Liang Cheng; Wanting Niu; Guoan Zhao; Jithin K Raju; Jun Huo; Bin Wu; Bo Yin; Yongsheng Song; Renge Bu Journal: Oncotarget Date: 2017-07-18